Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Application symbols : TAK save search
Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
Published: 2024-03-19 (Crawled : 17:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.07%
H: 0.0%
C: -0.96%
iclusig fda drug takeda approval application
Cognizant Helping to Modernize Infrastructure and Application Management as Part of Takeda's Digital Transformation
Published: 2024-01-25 (Crawled : 22:00) - prnewswire.com
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.27%
H: 0.38%
C: 0.07%
CTSH | $67.4 0.4% 0.4% 4.9M
|
Technology Services
|
| O: 0.33%
H: 0.42%
C: -1.63%
management cognizant application
HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan
Published: 2023-09-29 (Crawled : 09:00) - globenewswire.com
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.51%
H: 0.42%
C: -0.26%
HCM | $16.49 0.8% 0.79% 61K
|
Health Technology
|
| O: 0.59%
H: 0.82%
C: -0.65%
drug japan application submission
Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency
Published: 2023-06-15 (Crawled : 14:20) - globenewswire.com
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.31%
H: 0.78%
C: 0.69%
HCM | $16.49 0.8% 0.79% 61K
|
Health Technology
|
| O: 2.46%
H: 9.6%
C: 5.6%
authorization cancer application
Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review
Published: 2023-05-25 (Crawled : 23:00) - globenewswire.com
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.62%
H: 0.62%
C: -0.12%
HCM | $16.49 0.8% 0.79% 61K
|
Health Technology
|
| O: 7.45%
H: 3.66%
C: 2.06%
drug review treatment application
U.S. Food and Drug Administration Accepts Takeda’s Supplemental Biologics License Application for Use of TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older
Published: 2022-10-05 (Crawled : 17:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -1.47%
H: 0.9%
C: 0.37%
takhzyro drug children application license food hereditary angioedema
Immusoft Announces FDA Clearance of IND Application for ISP-001 for MPS I, the First Engineered B Cell Therapy to Enter into Clinical Trials
Published: 2022-09-01 (Crawled : 13:20) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.36%
H: 0.58%
C: 0.29%
isp-001 fda clearance trials application therapy mps-ih mps-i
Novavax Announces Submission of New Drug Application in Japan for Approval of COVID-19 Vaccine
Published: 2021-12-16 (Crawled : 05:00) - prnewswire.com
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 1.18%
H: 0.0%
C: 0.0%
NVAX | $3.99 2.57% 2.51% 2.9M
|
Health Technology
|
| O: 5.55%
H: 0.0%
C: 0.0%
covid-19 new drug application drug approval covid vaccine submission
GammaDelta Therapeutics Receives FDA Clearance of IND Application for GDX012, a Novel Allogeneic Variable Delta 1 Gamma-delta T Cell Cancer Therapy
Published: 2021-05-20 (Crawled : 11:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.82%
H: 0.81%
C: 0.23%
fda clearance fda therapy cancer application clearance t-cell
Karyopharm Announces European Medicines Agency's Validation of its Type II Variation Marketing Authorization Application for NEXPOVIO®
Published: 2021-04-26 (Crawled : 12:15) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.23%
H: 0.47%
C: -0.53%
KPTI | $1.16 -9.38% -10.34% 1.4M
|
Health Technology
|
| O: -0.11%
H: 5.12%
C: 4.58%
europe authorized application
Takeda Submits New Drug Application in Japan for Lanadelumab as a Preventive Treatment for Hereditary Angioedema Attacks
Published: 2021-03-12 (Crawled : 09:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -1.13%
H: 0.76%
C: 0.66%
new drug treatment drug application hereditary angioedema
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.